Comfortis

RSS

spinosad

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the Scientific Discussion (also part of the EPAR).

This EPAR was last updated on 04/10/2018

Authorisation details

Product details
Name
Comfortis
Agency product number
EMEA/V/C/002233
Active substance
spinosad
International non-proprietary name (INN) or common name
spinosad
Species
  • Dogs
  • Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QP53BX03
Publication details
Marketing-authorisation holder
Elanco GmbH
Revision
6
Date of issue of marketing authorisation valid throughout the European Union
11/02/2011
Contact address

Heinz-Lohmann-Str. 4
27472 Cuxhaven
Germany

Product information

24/09/2018 Comfortis - EMEA/V/C/002233 - T/0018

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other active parasiticides for systemic use

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides felis).

The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.

The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).

Assessment history

How useful was this page?

Add your rating